Part D Plan Spending Projections May Require Years Of Future Claims Data
This article was originally published in The Pink Sheet Daily
Medicare Payment Advisory Commission analyst says Part D sponsors may need “a few years of collecting claims information” before uncertainty regarding costs will subside. MedPAC staff is examining geographic variations in drug spending and the potential for variation in Part D premiums.
You may also be interested in...
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.
Paxil CR is back on pharmacy shelves after compliance concerns kept the antidepressant out of production for four months. The company expects to return Avandamet to the market within two weeks. FDA seized all lots of the products in March.